Company Dynamics - On October 19, the company presented impressive interim analysis data from the HARMONi-6 trial at The Lancet & ESMO [1] - The company revised the HARMONi-3 trial protocol to conduct independent statistical analyses based on histological types [2] Clinical Trial Results - The interim analysis of HARMONi-6 showed a median progression-free survival (mPFS) of 11.1 months compared to 6.9 months, with a hazard ratio (HR) of 0.60 (P<0.0001), indicating a significant improvement [1] - The absolute difference in mPFS between the two groups was 4.24 months, with consistent results across subgroups regardless of PD-L1 expression or liver metastasis [1] - Treatment-related serious adverse events (SAE) were reported at 32.3% for the experimental group versus 30.2% for the control group, with no overall survival (OS) data available yet [1] HARMONi-3 Trial Updates - The HARMONi-3 trial will be divided into two parts: sq-NSCLC (600 patients) and nsq-NSCLC (1000 patients), with separate statistical analyses planned [2] - Enrollment for sq-NSCLC is expected to complete in the first half of 2026, with OS analysis anticipated around the same time [2] - The nsq-NSCLC group aims to complete enrollment in the second half of 2026, with PFS event numbers expected in the first half of 2027 [2] Expansion of Clinical Indications - The company plans to initiate a global multi-regional clinical trial (HARMONi-GI3) for AK112 in colorectal cancer, based on promising II phase data [2] - The trial will compare AK112 combined with chemotherapy against bevacizumab combined with chemotherapy, with an enrollment target of 600 patients [2] Earnings Forecast and Valuation - The company maintains its earnings per share (EPS) forecasts for 2025 and 2026 at 0.09 CNY and 0.59 CNY, respectively [2] - The target price has been adjusted down by 18.2% to 184.00 HKD, reflecting a 50.1% upside potential [3]

Core Viewpoint - Fujian Haixi New Drug Creation Co., Ltd. (referred to as "Haixi New Drug") was listed on the Hong Kong Stock Exchange, with a closing price of 104.20 HKD on the first day, reflecting a 20.60% increase, but it dropped to 101.5 HKD the following day, a decrease of 2.59% [1]. Summary by Sections Share Issuance and Capital Structure - The total number of shares issued under the global offering was 11,500,000 H-shares, with 1,150,000 H-shares available for public offering and 10,350,000 H-shares for international offering [2]. - At the time of listing, the total number of shares issued was 78,707,270 [2]. Pricing and Proceeds - The final offering price was set at 86.40 HKD, resulting in total proceeds of 993.60 million HKD. After deducting estimated listing expenses of 53.47 million HKD, the net proceeds amounted to 940.13 million HKD [4][5]. Use of Proceeds - Approximately 52.0% of the net proceeds is expected to be used for ongoing investment in research and development to advance the drug pipeline and enrich the product portfolio. About 23.0% is anticipated for enhancing R&D capabilities and seeking collaboration opportunities. Additionally, 8.0% is planned for strengthening commercialization capabilities and expanding market influence, while 7.0% is allocated for improving and optimizing R&D and production systems, and 10.0% for working capital and other general corporate purposes [6]. Company Overview - Haixi New Drug is a commercial-stage pharmaceutical company that integrates R&D, production, and sales capabilities, with a pipeline of innovative drugs under development [6]. Financial Performance - The company's revenues for the years 2022, 2023, 2024, and the first five months of 2025 were 212.5 million, 316.6 million, 466.7 million, and 249.2 million RMB, respectively. The net profits for the same periods were 69.0 million, 117.5 million, 136.1 million, and 90.2 million RMB [7][8]. - The net cash flow from operating activities for the same periods was 85.3 million, 147.1 million, 163.9 million, and 80.1 million RMB [9]. Research and Development Pipeline - As of July 2025, Haixi New Drug has only four innovative drugs in the pipeline, all in early clinical stages. These include a multi-mechanism immune modulator C019199 for treating osteosarcoma and other malignancies, an oral small molecule drug HXP056 recently approved for clinical trials targeting wet age-related macular degeneration, and two other drugs for tumors and respiratory diseases still in preclinical research [10].

Market Performance - The Hang Seng Index rose by 2.4% to 25,859 points, while the Hang Seng China Enterprises Index increased by 2.5% to 9,233 points[1] - Total turnover in Hong Kong stocks was HKD 239.2 billion, lower than HKD 314.6 billion on the previous Friday, indicating market caution despite the rise[1] - Key sectors such as Energy, Consumer Discretionary, Information Technology, and Conglomerates saw increases of 2.8%, 3.3%, 3.2%, and 2.0% respectively, while Materials fell by 0.7%[1] Economic Indicators - China's Q3 GDP grew by 4.8%, surpassing the market expectation of 4.7%[3] - Industrial output in September rose by 6.5%, exceeding the forecast of 5.0%[3] - Retail sales increased by 3.0% year-on-year, aligning with expectations[3] Real Estate Trends - New home sales in 30 major cities reached 1.98 million square meters, down 25.4% year-on-year but improved from a previous decline of 41.4%[3] - New housing starts fell by 15.0% to 55.98 million square meters, a smaller decline compared to 19.8% in August[3] - The price index for new residential properties in 70 major cities dropped by 2.7% year-on-year, with first, second, and third-tier cities experiencing declines of 0.7%, 2.1%, and 3.4% respectively[3] Sector Highlights - Li Auto (9863 HK) saw a 6.2% increase in stock price after its founder and shareholders increased their holdings[4] - UBTECH (9880 HK) surged by 9.8% following a procurement order worth HKD 126 million for its latest humanoid robot[4] - The Hang Seng Healthcare Index rose by 1.3%, with major pharmaceutical companies showing stable performance despite market concerns[4]

Group 1 - The company, 旺山旺水, has passed the main board listing hearing of the Hong Kong Stock Exchange, with 中信证券 as its sole sponsor [1] - The company possesses nine innovative asset pipelines focusing on three therapeutic areas: neuropsychiatry, reproductive health, and viral infections [1] - Core products include LV232 for the treatment of major depressive disorder and TPN171 for erectile dysfunction [1] Group 2 - The company has achieved commercialization through the sales of dapoxetine, rebapentine, and products like TPN171 and VV116 in Uzbekistan [1] - According to Zhi Shi Consulting, the Chinese antiviral drug market, neuropsychiatric drug market, reproductive health drug market, and antiviral drug market are projected to grow from RMB 103.9 billion, RMB 36.2 billion, and RMB 20.3 billion in 2024 to RMB 123.5 billion, RMB 42.2 billion, and RMB 40.3 billion by 2035, respectively [1]

Core Viewpoint - Anke Biopharma announced the presentation of clinical research data for its innovative drug HuA21 at the ESMO annual meeting, highlighting its efficacy and safety in treating HER2-positive advanced gastric/gastroesophageal junction adenocarcinoma [1] Group 1: Company Developments - Anke Biopharma will present the latest research findings on HuA21, a recombinant anti-HER2 humanized monoclonal antibody injection, at the ESMO annual meeting in Berlin from October 17 to 21, 2025 [1] - The clinical study data for HuA21 in combination with trastuzumab and chemotherapy further confirms its good anti-tumor activity and tolerable safety profile [1] Group 2: Industry Implications - The results from the clinical research provide support for the Phase III clinical trial, potentially accelerating the drug development process [1]

Core Insights - The National Medical Products Administration has approved the launch of the innovative drug Remabizine Injection by Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd, which is used in conjunction with MediBeacon Inc's TGFR device to assess patients' glomerular filtration rate (GFR) [1][2] - This approval reflects Hangzhou's commitment to high-quality development in the biopharmaceutical industry, translating policy into practice through regulatory support and service empowerment [1][2] Group 1 - The Hangzhou Market Supervision Administration has implemented a "one-stop" service system to address the challenges of long, complex, and difficult drug development cycles, enhancing communication and support for key enterprises [1][2] - The city has established a collaborative "Hangzhou service model" that includes a three-level coordination mechanism to ensure timely communication of policies and responses to issues [1][2] Group 2 - The administration has adopted a full lifecycle service approach for the innovative drug project, optimizing drug registration and inspection processes to expedite approvals [2] - By coordinating with higher-level agencies and providing tailored support, the administration has significantly shortened the approval timeline for the drug, showcasing the acceleration of innovative services in Hangzhou [2] - The successful approval of Remabizine Injection exemplifies the synergy between market regulation and corporate innovation, with plans for continued reforms to further enhance the biopharmaceutical industry's development [2]

香港聯合交易所有限公司與證券及期貨事務監察委員會對本聆訊後資料集的內容概不負責，對其準確性或 完整性亦不發表任何聲明，並明確表示概不就因本聆訊後資料集全部或任何部分內容而產生或因倚賴該等 內容而引致的任何損失承擔任何責任。 四川百利天恒藥業股份有限公司 （「本公司」） （於中華人民共和國註冊成立的股份有限公司） 的聆訊後資料集 警告 本聆訊後資料集乃根據香港聯合交易所有限公司（「聯交所」）及證券及期貨事務監察委員會（「證 監會」）的要求而刊發，僅用作提供資訊予香港公眾人士。 本聆訊後資料集為草擬本，其內所載資料並不完整，亦可能會作出重大變動。您閱覽本文件， 即代表您知悉、接納並向本公司、其聯席保薦人、整體協調人、顧問或包銷團成員表示同意： 本公司招股章程根據香港法例第32章《公司（清盤及雜項條文）條例》呈交香港公司註冊處處長 註冊前，本公司不會向香港公眾人士提出要約或邀請。倘於適當時候向香港公眾人士提出要約 或邀請，準投資者務請僅依據呈交香港公司註冊處處長註冊的本公司招股章程作出投資決定； 有關文本將於發售期內向公眾刊發。 (a) 本文件僅為向香港公眾人士提供有關本公司的資料，概無任何其他目的；投資者不應根 ...

Core Insights - BaiLi TianHeng, an innovative pharmaceutical company, is accelerating its dual capital platform strategy by submitting a prospectus to the Hong Kong Stock Exchange after completing the largest A-share equity financing in the healthcare sector since the implementation of the comprehensive registration system [1][3] - The company's stock price has seen a significant increase, reaching a peak of 414.02 CNY per share by September 8, 2025, representing a cumulative increase of over 15 times since its initial public offering [1][2] - BaiLi TianHeng's recent A-share private placement raised a total of 3.764 billion CNY, with participation from top fund managers, marking a key step in its global expansion strategy [3][4] Financing and Market Position - The A-share private placement in September 2025 was the largest equity financing in the healthcare sector since the registration system was implemented, with 30 investors participating and 18 successfully winning bids [3][4] - The funds raised will be used entirely for innovative drug research and development, particularly for advancing the HIRE-ADC platform and GNC platform [3][4] - BaiLi TianHeng has become a star stock among institutional investors, with significant investments from prominent fund managers [3][4] Clinical Development and Breakthroughs - BaiLi TianHeng's core pipeline, including the drug BL-B01D1, has shown promising results in clinical trials, particularly in treating EGFR mutation non-small cell lung cancer [6][7] - The company reported a 100% objective response rate in a phase II study for the combination treatment of BL-B01D1 and Osimertinib, indicating a significant breakthrough in treatment options [6][7] - The drug has received breakthrough therapy designation from regulatory authorities, which will expedite its development and review process [7][8] Leadership and Vision - The company's rise is closely linked to the personal journey of its founder, Zhu Yi, who transitioned from academia to entrepreneurship and aims to establish BaiLi TianHeng as an entry-level multinational corporation (MNC) within five years [10][11][13] - Zhu Yi's vision includes developing blockbuster drugs and collaborating with MNCs, positioning BaiLi TianHeng as a key player in the global pharmaceutical landscape [10][13]

Core Viewpoint - ASKGENE LIMITED, a subsidiary of Aosaikang (002755), presented promising results for its investigational drug ASKB589 at the ESMO annual meeting, indicating significant potential in treating advanced gastric cancer [1] Group 1: Clinical Research Findings - ASKB589, a monoclonal antibody targeting CLDN18.2, combined with CAPOX (oxaliplatin and capecitabine) and PD-1 inhibitors, showed deep and durable tumor responses in patients with locally advanced, recurrent, or metastatic gastric and gastroesophageal junction adenocarcinoma [1] - The Ib/II phase clinical study demonstrated sustained disease control and clear survival benefits with longer follow-up [1] - These findings support the ongoing pivotal phase III clinical trials of ASKB589 in combination with chemotherapy and PD-1 inhibitors [1]

Core Viewpoint - The announcement highlights the promising results of ASKGENE LIMITED's investigational drug ASKB589 in combination with CAPOX and PD-1 inhibitors for the first-line treatment of advanced gastric cancer, showcasing significant survival benefits and reinforcing the drug's market competitiveness [1] Group 1: Clinical Research Findings - ASKB589, a monoclonal antibody targeting CLDN18.2, demonstrated deep and durable tumor responses and disease control in a Phase Ib/II clinical study for patients with locally advanced, recurrent, or metastatic gastric and gastroesophageal junction adenocarcinoma [1] - The latest data presented at the ESMO conference confirmed the significant and lasting anti-tumor activity of the ASKB589 combination therapy, marking the first report of overall survival (OS) benefits in advanced first-line gastric cancer patients [1] Group 2: Future Implications - The positive clinical data supports the ongoing pivotal Phase III clinical trials of ASKB589 in combination with chemotherapy and PD-1 inhibitors, enhancing the potential for market competitiveness of the company's product [1]